251 related articles for article (PubMed ID: 25001611)
21. A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
Jia X; Wang K; Xu L; Li N; Zhao Z; Li M
Breast; 2022 Dec; 66():31-39. PubMed ID: 36096071
[TBL] [Abstract][Full Text] [Related]
22. Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients.
Shiao J; Thomas KM; Rahimi AS; Rao R; Yan J; Xie XJ; DaSilva M; Spangler A; Leitch M; Wooldridge R; Rivers A; Farr D; Haley B; Kim DW
Breast Cancer Res Treat; 2017 Feb; 161(3):463-471. PubMed ID: 28005245
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
[TBL] [Abstract][Full Text] [Related]
24. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
25. Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Chen Y; Zhang J; Hu XC; Wang BY; Wang ZH; Wang LP; Cao J; Tao ZH; Du YQ; Zhao YN; Gong CC; Jin J
Ann Palliat Med; 2020 Sep; 9(5):3018-3027. PubMed ID: 32787354
[TBL] [Abstract][Full Text] [Related]
26. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
28. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
29. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Mayer IA; Zhao F; Arteaga CL; Symmans WF; Park BH; Burnette BL; Tevaarwerk AJ; Garcia SF; Smith KL; Makower DF; Block M; Morley KA; Jani CR; Mescher C; Dewani SJ; Tawfik B; Flaum LE; Mayer EL; Sikov WM; Rodler ET; Wagner LI; DeMichele AM; Sparano JA; Wolff AC; Miller KD
J Clin Oncol; 2021 Aug; 39(23):2539-2551. PubMed ID: 34092112
[TBL] [Abstract][Full Text] [Related]
30. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Saleh RR; Nadler MB; Desnoyers A; Meti N; Fazelzad R; Amir E
Cancer Treat Rev; 2021 Nov; 100():102283. PubMed ID: 34530283
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
Liedtke C; Rody A
Rev Recent Clin Trials; 2017; 12(2):73-80. PubMed ID: 28270088
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lu F; Hou Y; Chen Z; Jiang J; He X; Xia Y; Cao K; Chang L; Li W
Technol Cancer Res Treat; 2021; 20():15330338211016369. PubMed ID: 33977814
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
34. Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Liao Y; Fan Y; Wan Y; Li J; Peng L
Chemotherapy; 2013; 59(3):207-13. PubMed ID: 24335152
[TBL] [Abstract][Full Text] [Related]
35. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
Agrawal LS; Mayer IA
Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
[TBL] [Abstract][Full Text] [Related]
36. Triple-negative breast cancer: An institutional analysis.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
[TBL] [Abstract][Full Text] [Related]
37. Triple-negative breast cancer survival in Iranian patients.
Aghili M; Lashkari M; Farrokhpey AH; Izadi S
Acta Med Iran; 2013 Sep; 51(8):560-6. PubMed ID: 24026994
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
[TBL] [Abstract][Full Text] [Related]
40. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
